Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. / Bejon, Philip; Cook, Jackie; Bergmann-Leitner, Elke; Olotu, Ally; Lusingu, John; Mwacharo, Jedidah; Vekemans, Johan; Njuguna, Patricia; Leach, Amanda; Lievens, Marc; Dutta, Sheetij; von Seidlein, Lorenz; Savarese, Barbara; Villafana, Tonya; Lemnge, Martha M; Cohen, Joe; Marsh, Kevin; Corran, Patrick H; Angov, Evelina; Riley, Eleanor M; Drakeley, Chris J.

In: Journal of Infectious Diseases, Vol. 204, No. 1, 2011, p. 9-18.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Bejon, P, Cook, J, Bergmann-Leitner, E, Olotu, A, Lusingu, J, Mwacharo, J, Vekemans, J, Njuguna, P, Leach, A, Lievens, M, Dutta, S, von Seidlein, L, Savarese, B, Villafana, T, Lemnge, MM, Cohen, J, Marsh, K, Corran, PH, Angov, E, Riley, EM & Drakeley, CJ 2011, 'Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children', Journal of Infectious Diseases, vol. 204, no. 1, pp. 9-18. https://doi.org/10.1093/infdis/jir222

APA

Bejon, P., Cook, J., Bergmann-Leitner, E., Olotu, A., Lusingu, J., Mwacharo, J., Vekemans, J., Njuguna, P., Leach, A., Lievens, M., Dutta, S., von Seidlein, L., Savarese, B., Villafana, T., Lemnge, M. M., Cohen, J., Marsh, K., Corran, P. H., Angov, E., ... Drakeley, C. J. (2011). Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. Journal of Infectious Diseases, 204(1), 9-18. https://doi.org/10.1093/infdis/jir222

Vancouver

Bejon P, Cook J, Bergmann-Leitner E, Olotu A, Lusingu J, Mwacharo J et al. Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. Journal of Infectious Diseases. 2011;204(1):9-18. https://doi.org/10.1093/infdis/jir222

Author

Bejon, Philip ; Cook, Jackie ; Bergmann-Leitner, Elke ; Olotu, Ally ; Lusingu, John ; Mwacharo, Jedidah ; Vekemans, Johan ; Njuguna, Patricia ; Leach, Amanda ; Lievens, Marc ; Dutta, Sheetij ; von Seidlein, Lorenz ; Savarese, Barbara ; Villafana, Tonya ; Lemnge, Martha M ; Cohen, Joe ; Marsh, Kevin ; Corran, Patrick H ; Angov, Evelina ; Riley, Eleanor M ; Drakeley, Chris J. / Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. In: Journal of Infectious Diseases. 2011 ; Vol. 204, No. 1. pp. 9-18.

Bibtex

@article{26fc16f752cd4aac88c1e47bdbed2072,
title = "Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children",
abstract = "(See the article by Greenhouse et al, on pages 19-26.) Background. RTS,S/AS01(E) is the lead candidate malaria vaccine and confers pre-erythrocytic immunity. Vaccination may therefore impact acquired immunity to blood-stage malaria parasites after natural infection. Methods. We measured, by enzyme-linked immunosorbent assay, antibodies to 4 Plasmodium falciparum merozoite antigens (AMA-1, MSP-1(42), EBA-175, and MSP-3) and by growth inhibitory activity (GIA) using 2 parasite clones (FV0 and 3D7) at 4 times on 860 children who were randomized to receive with RTS,S/AS01(E) or a control vaccine. Results. Antibody concentrations to AMA-1, EBA-175, and MSP-1(42) decreased with age during the first year of life, then increased to 32 months of age. Anti-MSP-3 antibody concentrations gradually increased, and GIA gradually decreased up to 32 months. Vaccination with RTS,S/AS01(E) resulted in modest reductions in AMA-1, EBA-175, MSP-1(42), and MSP-3 antibody concentrations and no significant change in GIA. Increasing anti-merozoite antibody concentrations and GIA were prospectively associated with increased risk of clinical malaria. Conclusions. Vaccination with RTS,S/AS01E reduces exposure to blood-stage parasites and, thus, reduces anti-merozoite antigen antibody concentrations. However, in this study, these antibodies were not correlates of clinical immunity to malaria. Instead, heterogeneous exposure led to confounded, positive associations between increasing antibody concentration and increasing risk of clinical malaria.",
author = "Philip Bejon and Jackie Cook and Elke Bergmann-Leitner and Ally Olotu and John Lusingu and Jedidah Mwacharo and Johan Vekemans and Patricia Njuguna and Amanda Leach and Marc Lievens and Sheetij Dutta and {von Seidlein}, Lorenz and Barbara Savarese and Tonya Villafana and Lemnge, {Martha M} and Joe Cohen and Kevin Marsh and Corran, {Patrick H} and Evelina Angov and Riley, {Eleanor M} and Drakeley, {Chris J}",
year = "2011",
doi = "10.1093/infdis/jir222",
language = "English",
volume = "204",
pages = "9--18",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - JOUR

T1 - Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children

AU - Bejon, Philip

AU - Cook, Jackie

AU - Bergmann-Leitner, Elke

AU - Olotu, Ally

AU - Lusingu, John

AU - Mwacharo, Jedidah

AU - Vekemans, Johan

AU - Njuguna, Patricia

AU - Leach, Amanda

AU - Lievens, Marc

AU - Dutta, Sheetij

AU - von Seidlein, Lorenz

AU - Savarese, Barbara

AU - Villafana, Tonya

AU - Lemnge, Martha M

AU - Cohen, Joe

AU - Marsh, Kevin

AU - Corran, Patrick H

AU - Angov, Evelina

AU - Riley, Eleanor M

AU - Drakeley, Chris J

PY - 2011

Y1 - 2011

N2 - (See the article by Greenhouse et al, on pages 19-26.) Background. RTS,S/AS01(E) is the lead candidate malaria vaccine and confers pre-erythrocytic immunity. Vaccination may therefore impact acquired immunity to blood-stage malaria parasites after natural infection. Methods. We measured, by enzyme-linked immunosorbent assay, antibodies to 4 Plasmodium falciparum merozoite antigens (AMA-1, MSP-1(42), EBA-175, and MSP-3) and by growth inhibitory activity (GIA) using 2 parasite clones (FV0 and 3D7) at 4 times on 860 children who were randomized to receive with RTS,S/AS01(E) or a control vaccine. Results. Antibody concentrations to AMA-1, EBA-175, and MSP-1(42) decreased with age during the first year of life, then increased to 32 months of age. Anti-MSP-3 antibody concentrations gradually increased, and GIA gradually decreased up to 32 months. Vaccination with RTS,S/AS01(E) resulted in modest reductions in AMA-1, EBA-175, MSP-1(42), and MSP-3 antibody concentrations and no significant change in GIA. Increasing anti-merozoite antibody concentrations and GIA were prospectively associated with increased risk of clinical malaria. Conclusions. Vaccination with RTS,S/AS01E reduces exposure to blood-stage parasites and, thus, reduces anti-merozoite antigen antibody concentrations. However, in this study, these antibodies were not correlates of clinical immunity to malaria. Instead, heterogeneous exposure led to confounded, positive associations between increasing antibody concentration and increasing risk of clinical malaria.

AB - (See the article by Greenhouse et al, on pages 19-26.) Background. RTS,S/AS01(E) is the lead candidate malaria vaccine and confers pre-erythrocytic immunity. Vaccination may therefore impact acquired immunity to blood-stage malaria parasites after natural infection. Methods. We measured, by enzyme-linked immunosorbent assay, antibodies to 4 Plasmodium falciparum merozoite antigens (AMA-1, MSP-1(42), EBA-175, and MSP-3) and by growth inhibitory activity (GIA) using 2 parasite clones (FV0 and 3D7) at 4 times on 860 children who were randomized to receive with RTS,S/AS01(E) or a control vaccine. Results. Antibody concentrations to AMA-1, EBA-175, and MSP-1(42) decreased with age during the first year of life, then increased to 32 months of age. Anti-MSP-3 antibody concentrations gradually increased, and GIA gradually decreased up to 32 months. Vaccination with RTS,S/AS01(E) resulted in modest reductions in AMA-1, EBA-175, MSP-1(42), and MSP-3 antibody concentrations and no significant change in GIA. Increasing anti-merozoite antibody concentrations and GIA were prospectively associated with increased risk of clinical malaria. Conclusions. Vaccination with RTS,S/AS01E reduces exposure to blood-stage parasites and, thus, reduces anti-merozoite antigen antibody concentrations. However, in this study, these antibodies were not correlates of clinical immunity to malaria. Instead, heterogeneous exposure led to confounded, positive associations between increasing antibody concentration and increasing risk of clinical malaria.

U2 - 10.1093/infdis/jir222

DO - 10.1093/infdis/jir222

M3 - Journal article

C2 - 21628653

VL - 204

SP - 9

EP - 18

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 1

ER -

ID: 33582834